PT932417E - Conjugado de toxina nao antigenico e proteina de fusao de sistema receptor de interiorizacao - Google Patents

Conjugado de toxina nao antigenico e proteina de fusao de sistema receptor de interiorizacao

Info

Publication number
PT932417E
PT932417E PT97910793T PT97910793T PT932417E PT 932417 E PT932417 E PT 932417E PT 97910793 T PT97910793 T PT 97910793T PT 97910793 T PT97910793 T PT 97910793T PT 932417 E PT932417 E PT 932417E
Authority
PT
Portugal
Prior art keywords
protein
fuseo
interiorization
nax
receiver
Prior art date
Application number
PT97910793T
Other languages
English (en)
Portuguese (pt)
Inventor
David M Goldenberg
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Publication of PT932417E publication Critical patent/PT932417E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
PT97910793T 1996-10-17 1997-10-14 Conjugado de toxina nao antigenico e proteina de fusao de sistema receptor de interiorizacao PT932417E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2843096P 1996-10-17 1996-10-17

Publications (1)

Publication Number Publication Date
PT932417E true PT932417E (pt) 2003-07-31

Family

ID=21843399

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97910793T PT932417E (pt) 1996-10-17 1997-10-14 Conjugado de toxina nao antigenico e proteina de fusao de sistema receptor de interiorizacao

Country Status (11)

Country Link
US (4) US6083477A (enExample)
EP (1) EP0932417B1 (enExample)
JP (2) JP2001503253A (enExample)
AT (1) ATE233573T1 (enExample)
AU (1) AU729515B2 (enExample)
CA (1) CA2269060C (enExample)
DE (1) DE69719529T2 (enExample)
DK (1) DK0932417T3 (enExample)
ES (1) ES2191827T3 (enExample)
PT (1) PT932417E (enExample)
WO (1) WO1998016254A1 (enExample)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8771694B2 (en) * 1994-08-12 2014-07-08 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
DE69534530T2 (de) * 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6653104B2 (en) * 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
DE69719529T2 (de) * 1996-10-17 2003-12-11 Immunomedics, Inc. Nichtantigenes toxinkonjugat und fusionsprotein eines internalisierendes rezeptorsystems
ES2248898T3 (es) * 1997-05-02 2006-03-16 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Inmunotoxinas que comprenden una proteina onc dirigida contra celulas malignas.
US6187284B1 (en) * 1997-09-03 2001-02-13 Immunomedics, Inc. Fluorination of proteins and peptides for F-18 positron emission tomography
US6703488B1 (en) 1998-01-15 2004-03-09 Center For Molecular Medicine And Immunology Antibody/receptor targeting moiety for enhanced delivery of armed ligand
WO1999036437A1 (en) * 1998-01-15 1999-07-22 Center For Molecular Medicine And Immunology Antibody/receptor targeting moiety for enhanced delivery of armed ligand
US6869604B1 (en) * 1998-03-27 2005-03-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant anti-tumor RNAse
IL146005A0 (en) 1999-05-07 2002-07-25 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US7045283B2 (en) * 2000-10-18 2006-05-16 The Regents Of The University Of California Methods of high-throughput screening for internalizing antibodies
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
EP1425389B1 (en) * 2001-08-23 2011-11-02 Genmab A/S Human antibodies specific for interleukin 15 (il-15)
US7329405B2 (en) * 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
WO2003057732A2 (en) * 2002-01-14 2003-07-17 William Herman Multispecific binding molecules
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
WO2005069994A2 (en) * 2004-01-22 2005-08-04 Immunomedics, Inc. Folate conjugates and complexes
JP2008505853A (ja) 2004-04-13 2008-02-28 クインテセンス バイオサイエンシーズ インコーポレーティッド 細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
CA2583274A1 (en) * 2004-10-05 2007-02-15 Ochsner Clinic Foundation Enhancement of b cell proliferation by il-15
EA037929B1 (ru) 2005-03-23 2021-06-08 Генмаб А/С Антитела к cd38 человека и их применение
EP1919515A4 (en) 2005-08-31 2011-06-22 Immunomedics Inc F-18 PEPTIDES FOR PRECIBLE POSITRON EMISSION TOMOGRAPHY IMAGING
CA2646329C (en) 2006-03-20 2018-07-03 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
EP2044097A4 (en) * 2006-06-23 2010-10-06 Quintessence Biosciences Inc Modified ribonucleases
US8298801B2 (en) 2006-07-17 2012-10-30 Quintessence Biosciences, Inc. Methods and compositions for the treatment of cancer
ME03503B (me) 2006-09-26 2020-04-20 Genmab As Anti-cd38 plus kortkosteroidni plus ne-kortikosteroidni hemoterapeutik za tretiranje tumora
JPWO2008133141A1 (ja) * 2007-04-24 2010-07-22 東洋紡績株式会社 オスモチン組換えタンパク質およびその製造方法、並びにその利用
CA2698343C (en) 2007-09-04 2018-06-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
JP2010540681A (ja) * 2007-10-08 2010-12-24 クインテッセンス バイオサイエンシズ，インコーポレーテッド リボヌクレアーゼに基づく治療のための組成物及び方法
JP5547656B2 (ja) 2008-01-15 2014-07-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｃｄ４７によって媒介される食作用を操作するための方法
US11072655B2 (en) 2008-01-15 2021-07-27 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
ES2796085T3 (es) 2008-01-15 2020-11-25 Univ Leland Stanford Junior Marcadores de células madre de leucemia mieloide aguda
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
CN102227443B (zh) 2008-10-01 2014-05-14 昆特森斯生物科学公司 治疗性核糖核酸酶
EP3903829B1 (en) 2009-02-13 2023-05-03 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US10517969B2 (en) 2009-02-17 2019-12-31 Cornell University Methods and kits for diagnosis of cancer and prediction of therapeutic value
GB0905438D0 (en) * 2009-03-30 2009-05-13 Ge Healthcare Ltd Radiolabelling reagents and methods
BRPI1016209A2 (pt) 2009-04-16 2016-11-08 Charité Universitätsmedizin Berlin agente de alvejamento de linfócito-b para uso em um método para o tratamento de uma doença
LT2496691T (lt) 2009-11-02 2017-06-12 University Of Washington Terapinės nukleazės kompozicijos ir būdai
EP2506876B1 (en) 2009-12-02 2016-10-12 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
SI2580243T1 (sl) 2010-06-09 2020-02-28 Genmab A/S Protitelesa proti humanemu CD38
HRP20180564T1 (hr) 2011-04-29 2018-06-01 University of Washington, UW Center for Commercialization Terapijski pripravci nukleaze i postupci
CA2831572C (en) 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
BR112014022692A8 (pt) 2012-03-14 2021-07-20 Regeneron Pharma molécula de ligação de antígeno multiespecífica
CA2876706A1 (en) 2012-06-14 2013-12-19 Ambrx, Inc. Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
DK2900277T3 (da) 2012-12-13 2022-04-04 Immunomedics Inc Doser af immunokonjugater af antistoffer og sn-38 til forbedret effektivitet og reduceret toksicitet
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
EP3063275B1 (en) 2013-10-31 2019-09-25 Resolve Therapeutics, LLC Therapeutic nuclease-albumin fusions and methods
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
SG11201701867SA (en) 2014-09-09 2017-04-27 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
JP6678941B2 (ja) 2014-10-07 2020-04-15 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 抗体−薬物コンジュゲートのネオアジュバント使用
WO2016089960A1 (en) 2014-12-04 2016-06-09 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
JP6746845B2 (ja) 2015-04-22 2020-08-26 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 循環ｔｒｏｐ−２陽性癌細胞の単離、検出、診断及び／または特徴付け
MA42136A (fr) 2015-05-20 2018-03-28 Janssen Biotech Inc Anticorps anti-cd38 pour le traitement de l'amyloïdose à chaînes légères et d'autres tumeurs malignes hématologiques positives à cd38
US10668149B2 (en) 2015-06-22 2020-06-02 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
WO2016210108A1 (en) 2015-06-25 2016-12-29 Immunomedics, Inc. Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
PL3316885T3 (pl) 2015-07-01 2021-12-06 Immunomedics, Inc. Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
CN107849131A (zh) 2015-07-06 2018-03-27 瑞泽恩制药公司 多特异性抗原结合分子及其用途
CN108136012B (zh) 2015-08-07 2022-10-04 伊麦吉纳博公司 靶向分子的抗原结合构建体
JP6966424B2 (ja) 2015-09-09 2021-11-17 フレッド ハッチンソン キャンサー リサーチ センター 軟骨ホーミングペプチド
PH12018500950B1 (en) 2015-11-03 2023-09-20 Janssen Biotech Inc Subcutaneous formulations of anti-cd38 antibodies and their uses
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
DK3478830T3 (da) 2016-07-01 2024-05-21 Resolve Therapeutics Llc Optimerede binucleasefusioner og metoder
WO2018136614A1 (en) 2017-01-18 2018-07-26 Fred Hutchinson Cancer Research Center Peptide compositions and methods of use thereof for disrupting tead interactions
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
CN110475565A (zh) 2017-03-16 2019-11-19 光明之火生物科学公司 软骨归巢肽缀合物及其使用方法
KR102344616B1 (ko) 2017-05-30 2021-12-31 더 보드 오브 리젠츠 오브 더 유니버시티 오브 오클라호마 항-더블코르틴-유사 키나제 1 항체 및 사용 방법
EP3635009A1 (en) 2017-06-07 2020-04-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
WO2018232122A1 (en) 2017-06-15 2018-12-20 Blaze Bioscience, Inc. Renal-homing peptide conjugates and methods of use thereof
MX2020002070A (es) 2017-08-22 2020-03-24 Sanabio Llc Receptores solubles de interferon y usos de los mismos.
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
CA3086040A1 (en) 2017-12-19 2019-06-27 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
IL322464A (en) 2018-02-07 2025-09-01 Regeneron Pharma Methods and compositions for administering therapeutic protein
EP3793591A1 (en) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
JP7692897B2 (ja) 2019-09-10 2025-06-16 オブシディアン セラピューティクス， インコーポレイテッド 調節可能な制御のためのｃａ２－ｉｌ１５融合タンパク質
WO2022265912A1 (en) 2021-06-16 2022-12-22 Gundersen Lutheran Medical Foundation, Inc. Antibodies targeting an amphiregulin-derived cell surface neo-epitope

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837003A (en) * 1984-09-13 1989-06-06 Mallinckrodt, Inc. Radiolabeled antibody fragments
US5541297A (en) * 1988-04-01 1996-07-30 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
CA2086679A1 (en) * 1990-07-05 1992-01-06 Hermanus A. M. Verheul Receptor directed-toxin conjugates
US5346686A (en) * 1992-10-05 1994-09-13 Mallinckrodt Medical, Inc. Labelled interleukin-8 and medical uses thereof
US5591630A (en) * 1994-05-06 1997-01-07 Immunex Corporation Monoclonal antibodies that bind interleukin-15 receptors
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
DE69719529T2 (de) * 1996-10-17 2003-12-11 Immunomedics, Inc. Nichtantigenes toxinkonjugat und fusionsprotein eines internalisierendes rezeptorsystems
TW581136U (en) * 2002-10-08 2004-03-21 Nien Made Entpr Co Ltd Structure of wooden blind window

Also Published As

Publication number Publication date
JP2006089491A (ja) 2006-04-06
AU729515B2 (en) 2001-02-01
ATE233573T1 (de) 2003-03-15
US6399068B1 (en) 2002-06-04
US20050175582A1 (en) 2005-08-11
JP2001503253A (ja) 2001-03-13
ES2191827T3 (es) 2003-09-16
JP4056543B2 (ja) 2008-03-05
US7033572B2 (en) 2006-04-25
WO1998016254A1 (en) 1998-04-23
US6083477A (en) 2000-07-04
US20030031669A1 (en) 2003-02-13
DE69719529D1 (de) 2003-04-10
DK0932417T3 (da) 2003-04-14
EP0932417A1 (en) 1999-08-04
EP0932417B1 (en) 2003-03-05
AU4807997A (en) 1998-05-11
CA2269060A1 (en) 1998-04-23
DE69719529T2 (de) 2003-12-11
CA2269060C (en) 2009-04-07

Similar Documents

Publication Publication Date Title
PT932417E (pt) Conjugado de toxina nao antigenico e proteina de fusao de sistema receptor de interiorizacao
AR059470A2 (es) Receptor para una proteina de la clase vip3 , secuencia de adn, anticuerpos, metodo para identificar y aislar homologos del receptor y metodo para identificar compuestos como ligandos quimicos del receptor vip3
BR9406210A (pt) Ensaio de rapamicina
DE69729283D1 (de) GLYKOSYLIERTE IgG ANTIKÖRPER
NO963168L (no) Immunstimulatoriske monoklonale antistoffer
FR2604092B1 (fr) Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
ATE318147T1 (de) Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
FI830897A7 (fi) Menetelmä uusien konjugaattien valmistamiseksi, joissa entsyymi ja vasta-aine ovat sitoutuneet kovalekovalenttisella sidoksella.
EP1117692A4 (en) ANTIBODIES AGAINST TIE2 ANTAGONISTS
ES2110993T3 (es) Anticuerpos monoclonales especificos para la toxina b de clostridium difficile.
PT759942E (pt) Receptor de interleucina-15
TR199901636T2 (xx) �mm�nolojik hastal�klar�n tedavisi i�in terap�tik maddeler olarak ��z�n�r lenfotoksin-beta resept�rleri, anti-lenfotoksin resept�r� antikorlar� ve anti-lenfotoksin ba�� antikorlar�.
BR9710450A (pt) Anticorpo passivamente administrado que intensifica a eficiencia de conversÆo de alimenta-Æo
ATE350055T1 (de) Hämophilus influenzae adhärenz und penatrationsproteine
ES2061240T3 (es) Receptores solubles, truncados de interferon-gamma.
YU46858B (sh) Postupak za dobijanje imunoglobulinskih konjugata
PT826006E (pt) Transporte transepitelial de especies moleculares
EP1085088A4 (en) MONOCLONAL ANTIBODIES AND METHOD FOR DETECTING FIBRINE DEGRADATION PRODUCTS
FI925081A7 (fi) Menetelmä antigeenispesifisen, korkea affiniteetti monokloonisen vasta -aineen valmistamiseksi
ES1030632Y (es) Centro movil de recogida selectiva y simultanea de residuos urbanos.
EP0919617A4 (en) MONOCLONAL HUMAN ANTIBODY ANTI-MP52
BR1100559B1 (pt) mÉtodo de sondagem para identificar anticorpos especÍficos para antÍgenos selecionados.
DK557187A (da) Murin hybridoma lym-1, dermed fremstillet monoklonalt antistof og fremgangsmaade til fremstilling af antistoffet